State of the ART: Applying Up-to-Date Safety and Tolerability Data to Individualize HIV Care

In this video module, learn from experts about special considerations when selecting ARV medications during pregnancy including efficacy, pharmacokinetic and safety data.

Jean Rene Anderson, MD William R. Short, MD, MPH, AAHIVS Physicians: maximum of 0.5 AMA PRA Category 1 Credits™ Registered Nurses: 0.5 Nursing contact hours Pharmacists: 0.5 contact hours (0.05 CEUs) Released: August 12, 2022 Expired: No longer available for credit

Listen to experts converse about the latest data on weight gain and cardiometabolic toxicities with antiretroviral medications.

Priscilla Y. Hsue, MD Jens D. Lundgren, MD, DMSc Physicians: maximum of 0.5 AMA PRA Category 1 Credits™ Registered Nurses: 0.5 Nursing contact hours Pharmacists: 0.5 contact hours (0.05 CEUs) Released: August 23, 2022 Expired: No longer available for credit

Learn about ART safety in aging PWH and approaches to deprescribing ARV and non-ARV medications during this clinical conversation between experts.

Marta Boffito, MD, PhD, FRCP Julian Falutz, MD, FRCPC Physicians: maximum of 0.5 AMA PRA Category 1 Credits™ Registered Nurses: 0.5 Nursing contact hours Pharmacists: 0.5 contact hours (0.05 CEUs) Released: September 7, 2022 Expired: No longer available for credit

In this microlearning module, expert faculty share their approach to managing ART safety and tolerability in transgender individuals.

Jill Blumenthal, MD, MAS Jennifer Cocohoba, PharmD Physicians: maximum of 0.5 AMA PRA Category 1 Credits™ Registered Nurses: 0.5 Nursing contact hours Pharmacists: 0.5 contact hours (0.05 CEUs) Released: October 7, 2022 Expired: No longer available for credit

If you had told me 25 years ago that we would be obsessed with weight gain, I would have thought you were crazy. Yet here I am in clinic trying to decide what to do with possible ARV medication–related weight gain.

Joseph J. Eron, Jr., MD Released: October 31, 2022

Two-drug ART continues to be a nice simplification strategy for people with HIV. Read my commentary on recent data presented at the Fall 2022 Conferences highlighting safety and tolerability of 2-drug regimens.

Darcy Wooten, MD Released: December 23, 2022

Hear updates about ART safety and tolerability highlighting special populations such as those with cardiometabolic toxicities and aging PWH from summer 2022, including select studies from the AIDS 2022 meeting.

Jennifer Cocohoba, PharmD Joseph J. Eron, Jr., MD Physicians: maximum of 0.5 AMA PRA Category 1 Credits™ Registered Nurses: 0.5 Nursing contact hours Pharmacists: 0.5 contact hours (0.05 CEUs) Released: November 3, 2022 Expired: No longer available for credit

In this video module, get updates on ART safety and tolerability, including select studies from the IDWeek and HIV Glasgow 2022 meetings.

Eric K. Farmer, PharmD, BCPS, AAHIVP Darcy Wooten, MD Physicians: maximum of 0.5 AMA PRA Category 1 Credits™ Registered Nurses: 0.5 Nursing contact hours Pharmacists: 0.5 contact hours (0.05 CEUs) Released: January 24, 2023 Expired: No longer available for credit

Listen to expert insights from Dr. Jean Rene Anderson and Dr. William Short on their approach to optimizing HIV treatments during pregnancy.

Jean Rene Anderson, MD William R. Short, MD, MPH, AAHIVS Released: August 23, 2022

Listen as Priscilla Y. Hsue, MD, and Jens D. Lundgren MD, DMSc, share their insights on applying the latest safety and tolerability data of HIV treatments in patients with cardiometabolic toxicities.

Priscilla Y. Hsue, MD Jens D. Lundgren, MD, DMSc Released: October 4, 2022

Hear from experts about their approach to caring for older patients with HIV, including deprescribing ARV and non-ARV medications to address polypharmacy and other geriatric syndromes.

Marta Boffito, MD, PhD, FRCP Julian Falutz, MD, FRCPC Released: November 2, 2022

Listen as 2 experts discuss approaches to ART safety and tolerability in transgender individuals, including clinically relevant drug interactions and additional considerations such as gender-affirming care.

Jill Blumenthal, MD, MAS Jennifer Cocohoba, PharmD Released: December 7, 2022

Hear from expert faculty as they answer questions and discuss key considerations when evaluating potential ARV-related toxicities in special populations, including aging patients and populations with cardiometabolic toxicities.

Marta Boffito, MD, PhD, FRCP Jens D. Lundgren, MD, DMSc Released: January 17, 2023

This slideset provides an overview of the latest data on ART safety and tolerability, emphasizing unique populations such as pregnant women, aging patients, populations with cardiometabolic toxicities, and transgender persons.

Jean Rene Anderson, MD Jill Blumenthal, MD, MAS Marta Boffito, MD, PhD, FRCP Jennifer Cocohoba, PharmD Joseph J. Eron, Jr., MD Julian Falutz, MD, FRCPC Eric K. Farmer, PharmD, BCPS, AAHIVP Priscilla Y. Hsue, MD Jens D. Lundgren, MD, DMSc William R. Short, MD, MPH, AAHIVS Darcy Wooten, MD Released: November 28, 2022